<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139723">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133482</url>
  </required_header>
  <id_info>
    <org_study_id>1352.1</org_study_id>
    <secondary_id>2014-001061-27</secondary_id>
    <nct_id>NCT02133482</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate the safety and tolerability of BI
      639667 in healthy male subjects following oral administration of single rising doses up to
      700 mg.

      Secondary objectives are the exploration of the pharmacokinetics (PK) including dose
      proportionality as well as investigation of linearity and pharmacodynamics (PD) of BI 639667
      after single dosing and the assessment of the PK/PD relationship.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with drug-related adverse events</measure>
    <time_frame>up to 19 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 120 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 120 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 639667 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 639667 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 639667 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 639667 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 639667 dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 639667 dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 639667 dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose 7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 639667</intervention_name>
    <description>oral solution BI 639667, dose 1</description>
    <arm_group_label>BI 639667 dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 639667</intervention_name>
    <description>oral solution BI 639667, dose 5</description>
    <arm_group_label>BI 639667 dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo dose 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 639667</intervention_name>
    <description>oral solution BI 639667, dose 2</description>
    <arm_group_label>BI 639667 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 639667</intervention_name>
    <description>oral solution BI 639667, dose 4</description>
    <arm_group_label>BI 639667 dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 639667</intervention_name>
    <description>oral solution BI 639667, dose 6</description>
    <arm_group_label>BI 639667 dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 639667</intervention_name>
    <description>oral solution BI 639667, dose 3</description>
    <arm_group_label>BI 639667 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 639667</intervention_name>
    <description>oral solution BI 639667, dose 7</description>
    <arm_group_label>BI 639667 dose 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male subjects

          2. age of 18 to 50 years

          3. body mass index (BMI) of 18.5 to 29.9 kg/m2

        Exclusion criteria:

          1. Any finding in the medical examination (including BP, PR or ECG) is deviating from
             normal and judged as clinically relevant by the investigator

          2. Repeated measurement of systolic blood pressure greater than 140 mmHg, diastolic
             blood pressure greater than 90 mmHg, or pulse rate outside the range of 50 to 90 mmHg
             at screening

          3. Any laboratory value outside the reference range that the investigator considers to
             be of clinical relevance

          4. Any evidence of a concomitant disease judged as clinically relevant by the
             investigator

          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          6. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial
             medication (except appendectomy and simple hernia repair)

          7. Diseases of the central nervous system (such as epilepsy), other neurological
             disorders or psychiatric disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>May 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
